Andexanet alfa therapy showed No increased rate of thromboembolic events in spontaneous intracranial hemorrhage patients: A multicenter electronic health record study

John Vellek,Omar H. Tarawneh,Syed Faraz Kazim,Oluwafemi P. Owodunni,Sophia Arbuiso,Smit Shah,Alis J. Dicpinigaitis,Meic H. Schmidt,Rohini G. McKee,Richard Miskimins,Fawaz Al-Mufti,Christian A. Bowers

World Neurosurgery: X（2024）

引用 0|浏览1

暂无评分

摘要

•Intracranial hemorrhage accounts for two out of every three major intracranial hemorrhages.•Systemic anticoagulation is routinely prescribed for prevention of cerebrovascular accidents.•The FDA approved Andexanet alfa to treat life-threatening bleeding.•Andexanet alfa relationship to outcomes requires further investigation.

查看译文

关键词

Andexanet Alfa,Thromboembolism,Intracranial Hemorrhage,Anticoagulation

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要